Sygnature Discovery Limited
David Witty currently serves as Chief Science Officer at Sygnature Discovery since March 2024. David co-founded and has been the Director of WITNET LTD since November 2017, focusing on Drug Discovery and Biotech Operations. Between 2020 and 2023, David held the position of VP Chemistry and IP at Eliem Therapeutics, leading preclinical research for neuro-excitatory conditions. Their extensive experience includes roles as Editor for Elsevier's Progress in Medicinal Chemistry series, interim Chair of the Society of Chemical Industry's Board of Trustees, and various leadership positions at Convergence Pharmaceuticals and GSK, where David managed multiple medicinal chemistry programs. David's academic credentials include a d.Phil in Chemistry from the University of Oxford and postdoctoral research at the University of Texas at Austin.
This person is not in any teams
This person is not in any offices
Sygnature Discovery Limited
2 followers
Sygnature Discovery are a leading drug discovery CRO with expertise across a range of therapeutic and biological target classes. An expert partner in disciplines including Medicinal and Computational Chemistry, In Vitro and In Vivo Pharmacology, DMPK, supported by informatics.